No drugs specifically protect type 1 diabetes patients from kidney disease
For the one in three people living with type 1 diabetes who face the quiet threat of kidney failure, medicine has long offered only delay — never a remedy aimed at the root. Researchers at the University of Bristol have now demonstrated, in mice, that delivering a protective protein directly into kidney cells using gene therapy can reduce a key marker of kidney damage by 64 percent, more than doubling the threshold the American Diabetes Association considers clinically meaningful. The work does not yet constitute a treatment, but it constitutes something rarer: a new direction, where none existed before.
- One in three type 1 diabetes patients will develop kidney damage in their lifetime, and the disease advances silently — often undetected until the harm is already severe and irreversible.
- No existing drug addresses the cellular root cause of diabetic kidney disease; current treatments can only slow the deterioration, leaving millions without a genuine solution.
- Bristol researchers used a harmless virus to deliver the VEGF-C protein directly into the kidney cells of diabetic mice, targeting the fragile filtration structures that diabetes gradually destroys.
- The therapy produced a 64 percent reduction in albuminuria — a standard marker of kidney damage — more than doubling the 30 percent threshold the American Diabetes Association considers meaningful for slowing disease progression.
- The approach is the first of its kind tested in preclinical models, and while human clinical trials remain ahead, experts are calling it a potential turning point in how diabetic kidney disease might one day be treated.
One in three people with type 1 diabetes will develop kidney damage during their lifetime — a complication that advances quietly, often undetected until the harm is already severe. Doctors have long been able to slow this deterioration, but no drug has ever addressed what actually goes wrong at the cellular level. A team at the University of Bristol has now changed that equation, at least in mice.
The kidney's filtration system relies on delicate structures called glomeruli — tiny vascular networks that separate waste from blood. In diabetes, these filters gradually fail. Dr. Rebecca Foster and her colleagues hypothesized that a protein called VEGF-C could shore up these vessels and repair early damage, and they used a harmless virus to deliver it directly into the kidney cells of diabetic mice.
The results were striking. The therapy improved overall kidney function and specifically protected the filtration barrier. Measured by albuminuria — the leakage of albumin into urine, a standard marker of kidney disease — the reduction was 64 percent. The American Diabetes Association considers a 30 percent reduction meaningful enough to slow chronic kidney disease progression. This result more than doubled that threshold.
"Currently, there are no drugs specifically available to protect people with type 1 diabetes from kidney disease," Dr. Foster noted, framing the finding as filling a critical and long-standing gap. Dr. Faye Riley of Diabetes UK called it a potential turning point, describing the approach as tackling the root cause for the first time, while cautioning that the research remains early stage.
Published in Molecular Therapy, the work is a proof of concept in animals, not yet a treatment for humans. Many therapies that succeed in mice do not survive the translation to clinical trials. But for millions of patients who have faced this risk without any targeted option, the study offers something that did not previously exist: a direction forward.
One in three people with type 1 diabetes will develop kidney damage at some point in their lives. The disease creeps forward silently, often undetected until the harm is already severe. Until now, doctors have had no drugs that actually address what goes wrong at the cellular level—they can only slow the damage down. A team at the University of Bristol has changed that equation, at least in mice, by delivering a protective protein directly into kidney cells using gene therapy.
The kidney's filtration system depends on tiny structures called glomeruli, delicate networks of blood vessels that separate waste from blood. In diabetes, these filters gradually deteriorate. Researchers led by Dr. Rebecca Foster, an associate professor of microvascular medicine at Bristol Medical School, hypothesized that a protein called VEGF-C could shore up these failing vessels and repair early damage. Previous work had suggested the protein could work. The question was whether it could be delivered effectively enough to matter.
The team used a harmless virus as a delivery vehicle, programming it to carry VEGF-C directly into the kidney cells of diabetic mice. The results were striking. The therapy not only improved kidney function overall but specifically protected the filtration barrier itself. When the researchers measured albuminuria—the leakage of a protein called albumin into the urine, a standard marker of kidney disease—they found a 64 percent reduction. That figure matters because the American Diabetes Association considers a 30 percent reduction in albuminuria meaningful enough to slow the progression of chronic kidney disease. This result more than doubled that threshold.
Dr. Foster framed the finding as filling a critical gap. "Currently, there are no drugs specifically available to protect people with type 1 diabetes from kidney disease, despite their higher risk," she said. The absence of such treatments, despite the scale of the problem, underscores how little the medical field has understood about the root mechanisms of diabetic kidney damage until recently. This gene therapy approach, she emphasized, had not been tested in preclinical models before, making it genuinely novel.
Dr. Faye Riley, a research communications lead at Diabetes UK, called the work a potential turning point. "Kidney disease is a serious and life-altering complication of diabetes, that can progress silently over many years," she noted. "This novel approach tackles the root cause for the first time." She cautioned that the research remains early stage, but suggested it could lead to an entirely new protective strategy for people at risk of kidney failure.
The findings were published in Molecular Therapy, with Dr. Aldara Martin Alonso as the first author. The work represents a proof of concept in animals, not yet a treatment for humans. Clinical trials would need to follow, and many therapies that work in mice fail in people. But for the millions of type 1 diabetes patients who face a one-in-three chance of developing kidney damage, the possibility of a treatment that addresses the underlying cause rather than merely slowing its progression offers something that did not exist before: a direction forward.
Notable Quotes
Currently, there are no drugs specifically available to protect people with type 1 diabetes from kidney disease, despite their higher risk of developing kidney disease.— Dr. Rebecca Foster, Associate Professor of Microvascular Medicine at Bristol Medical School
This novel approach tackles the root cause for the first time.— Dr. Faye Riley, Diabetes UK
The Hearth Conversation Another angle on the story
Why does kidney damage in type 1 diabetes happen so silently? What makes it different from other complications?
The glomeruli—those tiny blood vessel filters—start to fail gradually, and the body doesn't send obvious warning signals. By the time someone notices symptoms, the damage is often already advanced. That's why this matters: catching and preventing it early is almost impossible with current tools.
So VEGF-C is just a protein. How does delivering it via a virus actually change anything at the cellular level?
The protein strengthens and repairs the blood vessels in the filter. Think of it as reinforcing the walls of a dam before cracks become catastrophic. The virus is just the delivery mechanism—it gets the protein where it needs to go without triggering an immune response.
A 64 percent reduction sounds impressive, but we're talking about mice. What's the realistic timeline for human trials?
That's the honest uncertainty. The preclinical work is solid, but moving to humans requires safety testing, dosing studies, all the standard phases. Years, probably. But for the first time, there's a specific mechanism to test.
Why hasn't this been tried before if the science seems straightforward?
Because understanding that VEGF-C could help and figuring out how to deliver it effectively to kidney cells are two very different problems. The delivery piece—using a virus to target the right cells—is the innovation here. It's not obvious until someone does it.
What happens to the mice after treatment? Do the kidneys stay protected?
The study shows the immediate protective effect, but long-term durability in animals and whether that translates to humans are still open questions. That's what future work will explore.
For someone with type 1 diabetes right now, what does this mean?
Honestly, not yet. But it means researchers have identified a real target and a way to hit it. That's the foundation everything else builds on.